Glytec Names Executive Director and General Manager of Outpatient Division

Glytec, developer of digital therapeutics and leader in insulin optimization, has hired Paula LeClair as executive director and general manager, Outpatient. In the diabetes industry, LeClair’s name is synonymous with transformation and innovation. She joins Glytec in a role that will tap her skills and experience leading operations and commercialization of emerging diabetes technologies and services.
 
LeClair most recently served as head of Operations for Onduo, a joint venture of Sanofi and Verily (an Alphabet company), where she was instrumental in driving vision and best practices for the company’s virtual diabetes clinic. Prior to Onduo, LeClair was president, CEO, and board member of Telcare, a medical device manufacturer backed by Sequoia Capital and Norwest Venture Partners and recognized as one of the first to market a U.S. Food and Drug Administration (FDA)-cleared cellular-enabled blood glucose meter. LeClair was a founding member of Telcare and ultimately directed its successful acquisition by BioTelemetry. Earlier in her career, LeClair served in various operations and finance roles with Insulet, 3COM, Cisco Systems, and Sun Microsystems.
 
“There are hundreds of devices, apps and pharmaceuticals aiming to improve the lives of people with diabetes,” said LeClair, “but Glytec’s ability to produce and sustain marked reductions in A1C, with little to no hypoglycemia, has proven there is truly no bigger opportunity to improve outcomes and reduce costs than their solutions for insulin optimization. I look forward to paving the pathways that will meet the demands of numerous near-term opportunities as well as long-term growth and diversification.”
 
LeClair has a master’s degree in healthcare delivery science from Dartmouth College, an MBA from Bentley University, a bachelor of science degree in mechanical engineering from the University of Notre Dame, and a bachelor of arts degree in engineering physics from Saint Anselm College. She is a member of the American Diabetes Association Community Leadership Board of New England.
 
“We are incredibly excited to have Paula become the newest member of our executive team,” said Glytec President and CEO Bob Leonard. “Her talents are immense and I can say with conviction that nobody is more aptly qualified to lead the tremendous and rapidly evolving opportunities that Glytec is cultivating in the outpatient diabetes space.”
 
Glytec is the pioneer of personalized digital therapeutics, enabling best practices for insulin optimization across the continuum of care. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes in the hospital and at home. Glytec combines evidence-based decision support technologies with expert clinical services to make insulin a more effective medication option for the millions unable to achieve their treatment goals, leading to reductions in A1C, hypoglycemia and other complications as well as avoidable emergency department visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Mass., and Greenville, S.C.